Diamyd Medical appoints Protein Sciences for production of its lead therapeutic diabetes vaccine

22-Dec-2005

Diamyd Medical AB announced that is has reached an agreement with Protein Sciences Corporation, a biopharmaceutical service company, for production of Diamyd(TM), its lead therapeutic diabetes vaccine. Under the terms of the agreement, Protein Sciences (PSC) will produce Diamyd Medical's lead therapeutic diabetes vaccine for Phase III trials, as well as prepare to file an Investigational New Drug Application (IND) with the U.S. food & Drug Administration (FDA). Diamyd Medical also is participating in Protein Sciences' current round of financing, with a US$3 million investment.

Diamyd(TM) is based on the beta cell antigen GAD (Glutamic Acid Decarboxylase), which is produced through a Recombinant Protein Expression System consisting of baculovirus (an insect virus) and insect cells. Protein Sciences (PSC) specializes in the development of influenza vaccines and other vaccines with insect based expression systems. PSC's cell line was recently approved by the FDA for the production of recombinant vaccines produced with insect based expression systems. Hence, PSC is a logical supplier for Diamyd Medical.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances